Cabozantinib (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cabozantinib" in French language version.

refsWebsite

Global rank French rank

68^th place

67^th place

1,735^th place

168^th place

1futuremedicine.com

low place

low place

2,374^th place

298^th place

274^th place

223^rd place

low place

7,741^st place

605^th place

35^th place

low place

low place

1euroinvestor.co.uk

low place

low place

ascopubs.org

Choueiri TK, Halabi S, Sanford BL et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial, J Clin Oncol, 2017;35:591-597.

euroinvestor.co.uk

(en) Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib. janvier 2011

europa.eu

ema.europa.eu

futuremedicine.com

Viola D, Cappagli V, Elisei R, Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer, Future Oncol, 2013;9:1083-1092

ipsen.com

« Ipsen reçoit un avis positif du CHMP pour Cabometyx® en association avec Opdivo® comme traitement en première »

lesechos.fr

investir.lesechos.fr

« Ipsen: résultats positifs d'un essai sur le Cabometyx contre le cancer de la prostate », sur Investir, 21 août 2023 (consulté le 21 août 2023)

nejm.org

Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 2015;373:1814-1823

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

springer.com

link.springer.com

Schmidt E, Lister J, Neumann M et al. Cabozantinib versus standard-of-care comparators in the treatment of advanced/metastatic renal cell carcinoma in treatment-naive patients: a systematic review and network meta-analysis, Target Oncol, 2018;13:205-216